Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

bloomberg.com - Margaryta Kirakosian - Sanofi Lines Up Takeover Target to Fix Pharma's Lowest Valuation
Sanofi Lines Up Takeover Target to Fix Pharma's Lowest Valuation
Bloomberg –

To understand why Sanofi is pursuing what would be the biggest takeover in the pharmaceutical industry in years, look no further than one number. Even after a surge since early October, the stock trades at 9 times estimated earnings, making Sanofi…

fool.com - Reuben Gregg Brewer - Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?
Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?
The Motley Fool –

Bristol Myers Squibb has an attractive 4.3% yield, and its P/E is below average for a drug maker. The pharma giant has a long history of successfully developing and marketing new drugs. Bristol Myers Squibb is facing a major patent expiration, but…

goldsea.com - Reuters - AI Is Shrinking Drug Discovery Timelines Says Big Pharma
AI Is Shrinking Drug Discovery Timelines Says Big Pharma
Goldsea –

A pharmacist checks weight of Paracetamol tablets inside a lab of a pharmaceutical company. REUTERS/Amit Dave/File Photo Artificial intelligence has sped up early-stage drug development work at some of the world's largest pharmaceutical companies…

investors.com - RACHEL FOX - Biotech Stock Ascendis Pharma Triggers Sell Rule; Here's Why You Shouldn't Give Up On It Yet
Biotech Stock Ascendis Pharma Triggers Sell Rule; Here's Why You Shouldn't Give Up On It Yet
Investor's Business Daily –

Ascendis Pharma (ASND) triggered the 7% sell rule on Friday as shares sold off alongside the broader market. This is a sign that investors who bought the breakout on Nov. 13 should be out of the stock. But given the Danish drugmaker's strong…

smh.com.au - Andrew Todd - ASX Runners of the Week: Black Rock, Mayne Pharma & Metal Hawk
ASX Runners of the Week: Black Rock, Mayne Pharma & Metal Hawk
The Sydney Morning Herald –

There's only one word to describe markets this week… Carnage. As of mid-market Friday, the ASX is in the midst of its seventh straight losing session, a plunge of more than six per cent that has now wiped out every cent of its 2026 gains. It…

channelnewsasia.com - Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines
Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines
CNA –

NEW YORK/LONDON, Nov 20: Artificial intelligence has sped up early-stage drug development work at some of the world's largest pharmaceutical companies this year, cutting by as much as half the time it takes to produce new molecules and move them…

yalibnan.com - AI is shrinking drug discovery timelines Big Pharma says - Ya Libnan
AI is shrinking drug discovery timelines Big Pharma says - Ya Libnan
Beirut –

Photo illustration – The purpose of slowing AI is to ensure that human wisdom and artificial intelligence continue advancing together toward a safer, healthier and more prosperous world. Artificial intelligence has sped up early-stage drug…

marketbeat.com - BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 34,980 Shares of Stock
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 34,980 Shares of Stock
MarketBeat –

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 34,980 shares of the business's stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $77.72, for a total transaction of…

alexberenson.substack.com - Alex Berenson - With measles rising, fighting the MMR vaccine hurts broader efforts to take on Big Pharma
With measles rising, fighting the MMR vaccine hurts broader efforts to take on Big Pharma
Unreported Truths –

(PART TWO on the resurgence of measles in the United States: Why exaggerating the risks of the measles vaccine is counterproductive. Part One, on what's really driving the rise in cases, is here.) Measles is back in the United States. And the…

marketbeat.com - Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Has Consensus Price Target of $59.20
Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Has Consensus Price Target of $59.20
MarketBeat –

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) has been given an average rating of 'Moderate Buy' by the seven brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell…

marketbeat.com - Royalty Pharma PLC $RPRX Stock: Voya Investment Management LLC Boosts Position
Royalty Pharma PLC $RPRX Stock: Voya Investment Management LLC Boosts Position
MarketBeat –

Voya Investment Management LLC grew its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 104.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned…

bloomberg.com - Ashleigh Furlong - Sanofi's New CEO Eyes Mega-Deal to Jump-Start Pipeline Rebuild
Sanofi's New CEO Eyes Mega-Deal to Jump-Start Pipeline Rebuild
Bloomberg –

Sanofi SA underwhelmed investors when it appointed Belen Garijo as chief executive officer this year. Just over six months into her tenure, she's considering the biggest pharma deal in years to help do exactly what shareholders have demanded: fix…

thehindu.com -  K. Sathiyanarayanan - A case for studying pure chemistry
A case for studying pure chemistry
The Hindu –

Chemistry is one of the oldest fields that have flourished over the past two and a half centuries since the discovery of oxygen by Antoine Lavoisier in 1777. In the early stages, physics and chemistry shared similarities in concepts. Then slowly…

seekingalpha.com - Edmund Ingham - Pharvaris: Orally Available HAE Therapy Appears To Be Ideal All Court Player
Pharvaris: Orally Available HAE Therapy Appears To Be Ideal All Court Player
Seeking Alpha –

I see Pharvaris as an intriguing long-term Buy and Hold, supported by deucrictibant's oral dosing, clinical results and versatility. PHVS faces an April 23, 2027 FDA decision for on-demand treatment; prophylaxis data showed an 83% attack reduction…

cbsnews.com - Megan  Cerullo - Anthropic is betting AI can help conquer disease and generate big bucks in the bargain
Anthropic is betting AI can help conquer disease and generate big bucks in the bargain
CBS News –

Fresh off its record-setting initial public offering, Anthropic now must show investors that it can sustain growth and generate profits. The company has a plan for that: curing some of the world's gnarliest diseases. In its IPO prospectus…

Receive a Daily briefing on Pharma Industry News

Get Started